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Elements of the Notch pathway regulate differentiation; we investigated the expression of such elements in epithelial ovarian
tumours. A total of 32 ovarian tumour samples (17 adenocarcinomas, three borderline tumours, 12 adenomas), two human ovarian
cancer (A2780, OVCAR3), and one ovarian surface (IOSE 144) cell lines were analysed. The expression of Notch pathway elements
was assessed by RT–PCR, real-time PCR (Notch 1), and by immunoblots (Notch 1 extracellular domain (EC), HES1). The
proliferation and colony formation of A2780 cells were measured after stable transfection with activated Notch 1 (intracellular
domain). Jagged 2, Delta-like-1, Manic Fringe, and TSL1 were expressed more frequently in adenocarcinomas whereas Deltex,
Mastermind, and Radical Fringe were more frequent in adenomas. Quantitative PCR revealed decreased Notch 1 mRNA in ovarian
adenocarcinomas compared with adenomas. The expression of Notch 1-EC protein was similar in benign and malignant tumours.
HES1 protein was strongly expressed in 18/19 ovarian cancers and borderline tumours but not in adenomas. Transfecting A2780
cells with active Notch 1-IC resulted in a proliferative and colony formation advantage compared to mock transfected cells. Thus,
Notch pathway elements are expressed in ovarian epithelial tumours and some of them are differentially expressed between
adenomas and carcinomas. The Notch pathway could be a target for the development of therapies for ovarian cancer.
British Journal of Cancer (2005) 93, 709–718. doi:10.1038/sj.bjc.6602719 www.bjcancer.com
Published online 23 August 2005
& 2005 Cancer Research UK
Keywords: ovarian adenoma; ovarian carcinoma; Notch
                                               
The cellular origin, histology, and biological properties of ovarian
neoplasms is heterogeneous and complex. About 90% of ovarian
tumours are adenomas and adenocarcinomas derived from
ovarian surface epithelium (OSE) of coelomic origin. Currently,
ovarian adenocarcinomas are thought to arise from OSE inclusion
cysts that form after OSE injury such as ovulation. The impaired
ability of inclusion cyst cells to acquire a mesenchymal phenotype
and the appearance of a gland-like differentiation of the otherwise
more pluripotent mesodermal precursors resembling OSE cells is
a hallmark of carcinogenesis (Scully, 1995). The molecular
pathogenesis of ovarian adenocarcinomas is unknown although
some mechanisms have been elucidated recently. Loss of function
mutations of tumour suppressor genes have been described such
as p53 in late stage tumours (Kupryjanczyk et al, 1993), PTEN in
endometroid ovarian carcinomas (Obata et al, 1998), BRCA1 and
BRCA2 in familial ovarian cancers (Ford et al, 1998; Kote-Jarai and
Eeles, 1999). Overexpression or amplification of oncogenes have
been described for PI3K (Philp et al, 2001) and its downstream
effector AKT2 (Cheng et al, 1992), EGF-R (Kohler et al, 1989),
cMyc (Tashiro et al, 1992), K-ras (Enomoto et al, 1991) and c-erbB
(HER2/neu) (Slamon et al, 1989). In a recent study we demon-
strated that p73, a member of the p53 family, is expressed in
ovarian adenocarcinoma but rarely in adenoma (Zwahlen et al,
2000). P73 and p63 increase the expression of the Notch ligands
Jagged 1 and 2 (Sasaki et al, 2002) leading to increased expression
of the Notch target HES1 in coculture assays. It appears likely that
deranged proliferation and cell fate determination processes are of
particular importance in the development of ovarian cancer. The
Notch pathway with its family of four mammalian Notch receptors
and their numerous ligands of the Delta and the Jagged/Serrate
group is playing an important role in cell fate determination
and organogenesis during the embryonic development and in
haematopoiesis (Artavanis-Tsakonas et al, 1999; Miele and
Osborne, 1999; Milner and Bigas, 1999). Figure 1 outlines the
Notch signalling network: the Notch genes encode transmembrane
receptor proteins of about 300kDa that undergo post-translational
modification by intramolecular cleavage and heterodimer forma-
tion. Upon interaction with a ligand, a complex cleavage process
of the Notch receptor is initiated, resulting in the release of
the intracellular c-terminal domain (approximately 110kDa). The
activating ligands, including Jagged 1, Jagged 2 (JAG 1 and JAG 2),
Delta-like-1, -3 and -4 (DLL1, DLL3 and DLL4), are mainly
expressed on the surface of neighbouring cells. The intracellular
Notch domain then translocates to the nucleus to interact with the
transcriptional repressor CBFl/RBP-Jk (Hsieh et al, 1996), turning
it into a transcriptional activator of numerous target genes such
as the HES1 gene, a member of the basic helix–loop–helix family
of transcription factors (Bailey and Posakony, 1995; Davis and
Turner, 2001). In developmental processes, Notch signalling often
results in the preservation of a small subset of proliferating
undifferentiated and multipotent progenitor cells. However, the
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cellular context. In a small subset of human acute lymphoblastic
T-cell leukaemia a constitutively active Notch 1 mutant functions
as an oncogene (Ellisen et al, 1991). Conversely activated Notch 1
and Notch 2 have been shown to result in a growth arrest of small
cell lung cancer cells, where it seems to act as a tumour suppressor
gene (Sriuranpong et al, 2001). Furthermore, Notch 1 has been
shown to function as a tumour suppressor gene in mouse skin
(Nicolas et al, 2003). In the present study, we show that many
elements of the Notch pathway are expressed in epithelial ovarian
tumours with carcinomas having higher HES1 protein expression
levels than adenomas indicating a stronger Notch pathway
activation. Furthermore, we demonstrate a proliferative and
survival advantage of stably Notch 1-IC (intracellular domain)
transfected A2780 ovarian carcinoma cells. We propose that the
Notch pathway could be a target for the development of novel
therapies for ovarian cancer.
MATERIAL AND METHODS
Patient characteristics and tumour specimens
Tumour samples were obtained from 32 patients who underwent
surgical resection of an ovarian tumour at the university hospitals
of Berne and Zurich, Switzerland. Sample collection was in
accordance with Swiss law and approved by the local institutional
review board. At the time of surgery no patient had received
chemotherapy. The tissues for the present study were selected by
the surgeons who were careful to submit large (41cm) pieces of
tissue that were macroscopically tumourous. Adjacent tissues were
used for the pathological diagnosis. The age range of the patients
was 40–83 years (median 61 years). Tumours were classified in
accordance with the WHO standard criteria (Tavassoli and
Devilee, 2003) as ovarian epithelial adenocarcinomas (17 cases),
epithelial ovarian cancers of low malignant potential (three cases)
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Figure 1 Notch signal transduction elements: (1) Post-translational modification of precursor Notch-protein includes cleavage by a Furin-like convertase
and glycosylation by members of the Fringe family (Radical (R), Manic (M), Lunatic (L)) in the trans-Golgi. (2) Adherence of Notch extracellular domain
(ECN) with Notch intracellular domain (ICN) results in mature Notch heterodimers that are transferred to the cell membrane. Receptor interaction with
ligands of the DSL-family (Delta, Serrate, Lag3) on neighbouring cells is modulated by Fringe modification of ECN. (3) E3 ubiquitin ligases (Mindbomb and
Neutralised) control the turnover of DSL-ligands on signalling cells. (4) Ligand availability is further regulated by the metalloprotease Kuzbanian, shedding the
extracellular domain of the transmembrane ligand protein. (5) Successful interaction of extracellular ligand regions with EGF-like repeats of ECN lead to (6)
successive cleavage of Notch transmembrane domain by the disintegrin-metalloprotease tumour necrosis factor-a-converting enzyme (TACE) and the
g-secretase Presenillin. (7) ICN is released and translocates to the nucleus where it interacts with CSL1, replacing CSL-repressors (CoR) and forminga
transcription complex with Mastermind-like factors (MAML) and transcriptional coactivators (CoA). (8) This transcriptional complex activates downstream
target genes, including members of the Hairy enhancer of split (HES) family of transcriptional repressors (bHLH). (9) These HES proteins excert their
function together with the Transducin-like enhancer of split (TSL) family of corepressors. Other target genes are tissue specific. (10) The half-life of ICN is
regulated by E3 ligases of the Sel-10 family before proteasome degradation. (11) A CSL-independent Notch pathway involves the interaction of ICN with
deltex, a cytosolic protein and positive regulator of Notch signalling. Adopted from Weng and Aster (2004).
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frozen in liquid nitrogen in the operating theatre immediately after
surgical removal.
Cell lines and culture conditions
Human ovarian adenocarcinoma cell lines A2780 and 2008 (kindly
provided by Dr S Howell, University of California San Diego, La
Jolla, CA, USA) were maintained in RPMI-1640 medium (Sigma, St
Louis, MO, USA) supplemented with 10% heat-inactivated fetal
calf serum (FCS, Sigma), the human ovarian adenocarcinoma cell
line OVCAR-3 (ATCC, Rockville, MD, USA) was maintained in
DMEM (Sigma) supplemented with 10% heat-inactivated FCS. The
human Hodgkin’s lymphoma cell line L540 (DSMZ, Braunschweig,
Germany) was maintained in RPMI-1640 medium supplemented
with 10% heat-inactivated FCS, and the human ovarian surface
epithelial cell line IOSE-144 (kindly provided by Dr N Auersperg,
University of Vancouver, Canada) was maintained in MCDB105
with L-glutamine (Sigma) and 25mM HEPESþMedium 199 with
Earle’s salt and L-glutamine (Sigma) (1:1) supplemented with 5%
heat-inactivated FCS and 50mgml
 1 gentamicin (Sigma).
RNA extraction and RT–PCR
After homogenisation of tumours using a tissue homogeniser
(Polytron, Kinematica, Littau, Switzerland), total RNA was
extracted using the RNeasy/QIAamp Kit (Quiagen, Basel, Switzer-
land). Contaminating genomic DNA was removed by DNase I
treatment according to the manufacturer’s instructions (RNase-
Free DNase Set, Quiagen). Reversed transcription was performed
using 1mg total RNA, 0.8mg primer oligo dT15 primers (Roche,
Rotkreuz, Switzerland), 1.3ml PCR Nucleotide Mix, 10mM
deoxynucleotide triphosphate (Roche), 28U rRNasin (Promega,
Wallisellen, Switzerland), 5ml M-MLV 5 buffer (Promega), 200U
M-MLV reverse transcriptase (Promega) in a final volume of 25ml.
PCR was carried out at least as duplicates as follows: 5ml cDNA as
template were added to a mastermix made of 3ml1 0  PCR
bufferþMg (Roche), 3ml glycerol, 3ml PCR nucleotide mix, 1mM
deoxynucleotide triphosphate (Roche), 0.8U Taq DNA polymerase
(Roche), sense and antisense primers with a final concentration of
266nM. Thermocycler conditions were as described elsewhere
(Zwahlen et al, 2000). The annealing temperature was optimised
for each primer pair and 35–37 PCR cycles were applied. The
following human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) primers were used for quality control of RT-PCR for
each cDNA generated, sense: 5-GAGCTGAACGGGAAGCTCACT
GG-3; antisense: 5-CAACTGTGAGGAGGGGAGATTCAG-3. PCR
products were separated on a 1% agarose gel containing ethidium
bromide. The primers used for the detection of cDNA of Notch
pathway genes are shown in Table 1.
Real-time quantitative RT–PCR for hNotch 1
TaqMan real-time RT–PCR (TaqMan PCR detector 7700, Perkin-
Elmer Applied BioSystems, Rotkreuz, Switzerland) was used for
relative quantification of hNotch 1 (Gene Bank accession no.
AF308602) gene expression in human ovarian tumour samples and
cell lines as described previously (Leonard et al, 2000). The
preparation of cDNA was carried out as described above. Dual
labelled (FAM/TAMRA) gene-specific probes and TaqMan Uni-
versal PCR Master Mix (Perkin-Elmer Applied BioSystems,
Rotkreuz, Switzerland) were used. Sequences of hNotch 1 specific
oligonucleotides were as follows, probe: 50-CCGCTCTGCAGCCGG
GACA-30; forward primer: 50-CACTGTGGGCGGGTCC-30; reverse
primer, 50-GTTGTATTGGTTCGGCACCAT-30 (Shou et al, 2001).
Notch 1 gene expression was normalised to the expression level of
the housekeeping gene porphobilinogen deaminase (PBGD, Gene
Bank accession no. Ml8799). Sequences for PBGD-specific
oligonucleotides were as follows, probe: 50-TGCGGCTGCAACGGC
GGAAGAAA-30; forward primer: 50-GGAGCCATGTCTGGTAACG
GCA-30; reverse primer: 50-GGTACCCACGCGAATCACTCTCA-30.
Primers were used at a final concentration of 300mM; the final
probe concentration used was 150mM. In total, 2.5ml cDNA and
12.5ml TaqMan Universal PCR Master Mix were added to a final
reaction volume of 25ml. A total of 45 TaqMan PCR-cycles were
run under standard conditions.
Western blot analysis
Cell extracts were prepared as described (Zwahlen et al, 2000).
Briefly, after tissue homogenisation and sonication, cells were
lysed in RIPA buffer (150mM NaCl, 1.0% Nonidet P-40, 0.5%
sodium desoxycholate, 0.1% sodium dodecyl sulfate, 50mM Tris,
pH 8.0) on ice for 30min, followed by centrifugation for 20min at
41C. Quantification was done by Bradford assay (Bio-Rad,
Glattbrugg, Switzerland). In all, 50mg total cellular protein per
lane were size fractioned on a 7% tris-acetate gel (Invitrogen,
Paisley, UK) for Notch 1 detection or on a 4–12% tris-glycine
gradient gel (Invitrogen) for HES1 detection and blotted onto
nitrocellulose (Protan; Schleicher and Schuell, Kassel, Germany).
Equal loading and transfer efficiency was visually checked by
Table 1 RT-PCR primers for detection of Notch pathway genes
Gene Gene Bank accession number Annealing temperature (1C) Forward primer Reverse primer PCR product (bp)
Notch 2 XM_016986 58 5-gatgccacctgaacaactgc-3 5-tgacaacagcaacagcaagg-3 407
Notch 3 XM_009303 58 5-ttgctgctggtcattctcg-3 5-tcctcttcagttggcattgg-3 476
Jagged 1 NM_000214 58 5-agcgacctgtgtggatgag-3 5-ggctggagactggaagacc-3 333
Jagged 2 NM_002226 58 5-tctctgtgaggtggatgtcg-3 5-cagtcgtcaatgttctcatgg-3 327
Delta-like-1 NM_003836 58 5-ccacgcagatcaagaacacc-3 5-ttgctatgacgcactcatcc-3 336
Delta-like-2/4 AB036931/AB043894 60 5-ccaactatgcttgtgaatgtcc-3 5-tgtggagaggtcggtgtagc-3 353
Kuzbanian E33199 58 5-gcggtgcagattagtagatgc-3 5-aggcactaggaagaaccaagg-3 352
Presenillin XM_007441 58 5-agactggaacacaaccatagcc-3 5-caatagtgcaaggtggtcagg-3 360
Manic- Fringe U94352 60 5-gtggaatgatggcagaatcc-3 5-gctgtggatgattgtcttgg-3 384
Radical- Fringe U94353 58 5-tgacaattatgtgaacgcaagg-3 5-ccaggtgagagtggaagagg-3 347
Numb AF171938 58 5-cgaccgatggttagaagagg-3 5-gaatgtctgctgcctgacc-3 367
Mastermind NM_014757 58 5-tcagaactccgcgaataacc-3 5-tgctggctgctgagatagg-3 351
HES 1 NM_005524 58 5-ccagtttgctttcctcattcc-3 5-tcttctctcccagtattcaagttcc-3 254
Deltex NM_004416 61 5-gatgcctgtgaatggtctgg-3 5-ggatggtgatgcagatgtcc-3 362
HERP 2 AF232239 62 5-gaggtggagaaggagagtgc-3 5-ctccgatagtccatagcaagg-3 314
TSL 1 NM_005077 58 5-ccaaggtctgcttctcatgc-3 5-gtacttgtcaggcttgttcacg-3 320
TSL 4 XM_042357 58 5-caaggcagagctgacatcc-3 5-cacattgctgttctccatcc-3 346
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sPonceau staining. Membranes were blocked for 3h at room
temperature with 5% w/v nonfat dry milk/TBS and Tween-20 (0.05%
w/v). Membranes were incubated with rabbit polyclonal anti-
Notch 1 antibodies (H-131, Santa Cruz, Nunningen, Switzerland)
for the detection of the extracellular domain of Notch 1. For the
detection of HES1, membranes were incubated with a rabbit
polyclonal anti-HESl antibody (kindly provided by Dr Sudo, Toray
Industries, Kanagawa, Japan). Detection of primary antibody
binding was done with donkey antirabbit horseradish peroxidase
conjugated antibodies, followed by enhanced chemiluminescence
detection (all from Amersham, Zurich, Switzerland). Equal loading
was assessed visually by detection of actin with a rabbit polyclonal
antibody (A2066, Sigma) after stripping and reblocking of the
membranes. The Hodgkin’s Lymphoma cell line L540 served as a
positive control for Notch 1 extracellular domain expression
(Jundt et al, 2002). HES1 protein was in vitro synthesised by
the TNT T7 Quick Coupled Transcription/Translation System
(Promega) from the mHESl cDNA in pBluescript SKþ (kindly
provided by Dr R Kageyama, Kyoto University, Japan). Each
experiment was repeated at least twice, and the strenght of
expression was scored visually by assigning one of four scores
(strong, intermediate, weak, and absent; cf, Figure 2).
Transfection and colony forming assayþproliferation
assay
The ovarian adenocarcinoma cell line A2780 was transfected with
hNotch 1-IC-HA (pCDNA3 Invitrogen) as previously described
(Chen et al, 1997). Empty vector transfected cells were used as
controls. Transfection was done by electroporation, applying 5mg
plasmid DNA per 1 million cells. Selection was performed with
G418 at 600mgml
 1. The resultant G418 resistant clones were
pooled and used directly for colony forming and proliferation
assays. The latter was carried out by the XTT method according
to the manufacturer’s instructions (Biological Industries, Beit
Haemek, Israel). In total, 1000 cells were seeded in 9cm wells in
selection medium as indicated above. XTT assay was performed on
days 4, 7, 8, 10 and 12. For the colony forming assays 300 cells of a
single cell suspension were seeded in 10cm Petri dishes and
counted 7 days after when the colonies were visible by eye. All
experiments were performed in triplicate.
Dual luciferase-assay
Notch pathway activation of the stably hNotch 1-IC-HA transfected
A2780 was tested by transient transfection of 1 million cells from
pooled G418-resistant clones, using electroporation, with 5mgo fa
reporter plasmid containing the Notch/RBP-Jk-responsive region
of the Hairy and Enhancer of Split homologue-1 (HES1) promoter
as described previously (Rangarajan et al, 2001). Empty vector
transfected cells served as controls. In all cases 100ng of a renilla
luciferase expression plasmid (pRL-CMV, Promega) were cotrans-
fected. The Dual-Luciferase reporter assay (Promega) was
performed according to the manufacturer’s specifications 48 and
72h after transfection.
RESULTS
RT–PCR analysis of the expression pattern of elements of
the notch pathway in ovarian tumours
To test the hypothesis that the Notch pathway could be involved
in the pathogenesis of ovarian carcinomas we studied the mRNA
expression pattern of some of its elements by RT–PCR in 32
ovarian tumour samples (17 ovarian adenocarcinomas, three
ovarian cancers of low malignant potential, 12 ovarian adenomas),
three ovarian cancer cell lines (A2780, OVCAR-3, 2008), and one
human ovarian surface epithelial cell lines (IOSE-144). GAPDH was
detected in all samples, indicating similar quality of extracted
mRNA. The results are summarised in Table 2 and representative
samples of RT–PCR products are shown in Figure 2. Notch 1 (see
below), Jagged 1, Delta-like-2/4, HES1 and Presenillin expression
was detectable in all ovarian adenocarcinomas and ovarian
adenomas (for Notch 1 only real-time RT–PCR data are shown).
In contrast, ovarian adenocarinomas were more frequently
positive than adenomas for the Notch ligands Jagged 2 (P¼0.04,
Fisher’s exact test, two-sided probabilities are shown without
adjustment for multiple testing) and Delta-like-1 (P¼0.056), for
the modulator of ligand specificity Manic Fringe (P¼0.0007) and
for the downstream transcription factor Transducin-like Enhancer
of split-1 (TSL1; P¼0.01). On the other hand, slightly higher
frequencies of expression were found in adenomas for Deltex and
Mastermind, and Radical Fringe.
The expression pattern of elements of the Notch pathway in
ovarian cancer cell lines was similar to ovarian adenocarcinomas
with the exception of Jagged 2, Delta-like-1, Delta-like-2 and TSL4
that were expressed at a lower frequency.
Real-time quantitative RT–PCR for hNotch 1
Altered Notch 1 expression has been found in certain haematologic
malignancies and solid tumours. To study the Notch 1 mRNA
expression level we used TaqMan real-time quantitative RT–PCR
for the screening of human ovarian tumours and cell lines. Primers
and probes were selected for the intracellular domain of Notch 1.
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Figure 2 RT–PCR results of representative examples (13¼ovarian adenocarcinoma, 33¼borderline tumour, 28¼ovarian adenoma) for Notch
pathway elements. 0, no signal detected. þ, mRNA detected by RT–PCR. The results of duplicate experiments were identical.
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sTable 2 mRNA expression of elements of the Notch pathway
Receptors Ligands Modulators Downstream effectors Cleavage enzymes
Case
Notch
2
Notch
3 Jagged 1 Jagged 2 Delta-like-1 Delta-like-2/4 Numb M. Fringe R. Fringe Deltex Mastemind HES l HERP 2 TSL 1 TSL 4 Kuzbanian Presenillin
Ovarian adenocarcinoma (N¼17)
1 + + + + + ++ + + 0 + + + + + ++
2 + + + + + + +++ +++ 0 + + + +
30 + + 0 0 + + +0 + 0 + 0 + + 0 +
4 + + + + + ++ + + + 0 + 0 0 + ++
7 + + + + + ++ + + 0 0 + 0 + + ++
1 0 + + + + + + +++ +++ 0 + + + +
1 1+ 0 + + + + ++ 0+ 0 + 0 + 0+ +
1 3 + + + + + + +++ +++ 0 + + + +
1 6 + + + + + + +++ +++ 0 + + + +
1 7 + + + + + + +++ +++ 0 + + + +
1 9 0++ + + + + 0 0 + + +0+ + + +
2 0 + + + + + + +++ +++ 0 + + + +
2 1 + + + + + + +++ +++ + + + + +
23 + 0 + 0 + + + + + + 0 + 0 + + + +
2 6 + + + + + + +++ +++ 0 + + + +
3 1 + + + + + + +0 + +++ 0 + + + +
37 + + + + + + + 0 + 0 + + 0 + + + +
Frequencies 88% 88% 100% 88% 94% 100% 100% 82% 82% 82% 70% 100%
12% 94% 94% 94% 100%
15/17 15/17 17/17 15/17 16/17 17/17 17/17 14/17 14/17 14/17 12/17 17/177 12/17 16/17 16/17 16/17 17/17
Borderline tumours (N¼3)
90 ++ 00 ++ + 00 0 + 00 0 + +
33 + 0 + + ++ + 0 ++ 0 + 0 ++ + +
34 + + + + ++ + 0 + +++ 0 ++ + +
Frequencies 67% 67% 100% 67% 67% 100% 100% 33% 67% 67% 33% 100%
0% 67% 67% 100% 100%
2/3 2/3 3/3 2/3 2/3 3/3 3/3 1/3 2/3 2/3 1/3 3/3 0/3 2/3 2/3 3/3 3/3
Ovarian adenomas (N¼12)
14 + 0 ++ 0 ++ 0 ++ 0 + 0 ++ + +
15 +++ + 0 ++ 0 + +++ 00 ++ +
24 +++ 0 ++ + 0 + +++ 00 ++ +
25 +++ 00 ++ 0 + +++ 00 ++ +
27 +++ 00 ++ 00 +++ 00 0 ++
28 0 ++ 00 + 00 ++ 0 + 00 ++ +
29 +++ 00 ++ 0 + +++ 00 ++ +
32 + + + + + + +++ +++ 0 ++ + +
35 +++ + 0 ++ 0 + +++ 0 ++ + +
36 +++ + + + + 0 + +++ 0 ++ + +
38 0 ++ 0 ++ 0 + 0 + 0 + 0 ++ 0 +
39 +++ + + + + 0 + +++ 0 ++ + +
Frequencies 83% 92% 100% 50% 58% 100% 83% 17% 83% 100% 75% 100%
0% 50% 92% 92% 100%
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Figure 3 Notch 1 mRNA real-time PCR, normalised for PBGD
(arithmetic means of triplicate measurements).
Table 3 Western blot analysis of Notch 1-EC (extracellular domain) and
HESl protein
Case Notch l-EC HES l
Ovarian adenocarcinomas
1+ +
2+ +
3N D N D
4+ +
7+ + +
10 + ++
11 + +
13 + +
16 + (+)
17 + +
19 + +
20 ++
21 ++ ++
23 + +
26 + +
31 + ++
37 + +
Borderline tumours
9+ + +
33 + +
34 + ++
Ovarian adenomas
14 + +
15 (+) +
24 ND ND
25 + +
27 (+) +
28 + +
29 (+) (+)
32 ND ND
35 ND ND
36 + (+)
38 + 0
39 + (+)
Cell lines
A2780 +++ +++
2008 + +++
OVCAR-3 ++ +++
IOSE 144 + +++
ND¼not done; 0¼negative; (+)¼weak positive; +¼positive; ++¼marked
positive; +++¼strong positive.
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adenocarcinomas (median expression level relative to PBGD:
0.35), but a tendency towards decreased Notch 1 expression in
comparison to ovarian adenomas (median:0.705; Figure 3).
Expression pattern of Notch 1 and HES1 protein
We further investigated the protein expression pattern of full
length Notch 1 (330–220kDa), the Notch 1 extracellular domain
(Notch 1-EC, 120kDa) and of the downstream transcription factor
HES1 (32kDa) in 28 of the 32 ovarian tumours (16 ovarian
carcinomas, three borderline tumours, nine ovarian adenomas),
in three human ovarian cancer cell lines and one ovarian surface
epithelium cell line. In four ovarian tumours the amount of
extracted protein was insufficient for immunoblotting. The
Hodgkin’s lymphoma cell line L540 served as positive control for
Notch 1-EC expression and in vitro translated mHESl cDNA for
HES1 protein expression. Results are summarised in Table 3 and
representative samples are depicted in Figure 4. Similar amounts
of b-actin protein expression were detected in all tumour and cell
line specimens. Notch 1 and Notch 1-EC protein was expressed in
all ovarian cancers, borderline tumours and ovarian adenomas at
similar levels. In ovarian cancer cell lines the expression of Notch
was a strong expression of Notch 1-EC in A2780, an intermediate
expression in OVCAR-3, but a lower expression level in IOSE-144.
The expression level of HES 1 protein on the other hand trended
to be higher in the malignant than in the benign tumours: in
invasive adenocarcinomas and borderline tumours, the expression
was intermediate in 11 out of 19 and strong in seven out of 19
samples, whereas in ovarian adenomas five out of nine specimens
showed intermediate and four out of nine weak or absent
expression. However, in all ovarian adenocarcinoma and surface
epithelium cell lines the HESl protein expression was very high at
similar levels.
Stable transfection of Notch 1-IC in A2780 ovarian
adenocarcinoma cell line
The observation of a consistent expression of Notch 1 protein in
ovarian adenocarcinomas and adenomas does not prove that
Notch 1 signalling is actually active. The expression of HESl could
be induced by other upstream factors such as Notch 2 or possibly
Sonic Hedgehog (Shh) (Solecki et al, 2001). Therefore, we
investigated the biological relevance of activated Notch 1 by stably
transfecting the cell line A2780 with Notch 1-IC, the functionally
active intracellular domain of the Notch 1 heterodimer, in order
to increase the degree of Notch pathway activation. The biological
activity of transfected Notch 1-IC was confirmed by a dual
luciferase reporter-plasmid assay. The normalised luciferase
activity was 127% higher in hNotch 1-IC-HA stably transfected
A2780 than in empty vector controls 48h after transient
transfection and 72% after 72h. When compared to the wild type,
the hNotch 1-IC-HA transfected A2780 cells derived from pooled
clones showed a proliferative advantage from day 7 onwards after
cells reached confluence (Figure 5). The metabolic activity
330−220 kDa
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32 kDa HES-1
37 kDa Actin
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Figure 4 Western blots for Notch 1 (full-length and extracellular domain (EC)) and HES-1 in ovarian adenocarcinomas, borderline tumours, adenomas
and cell lines (ovarian adenocarcinoma A2780 and OVCAR-3, ovarian surface epithelium IOSE-144 and Hodgkin’s lymphoma L540).
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3277.5% higher in the Notch 1-IC stably transfected A2780 cells
compared to mock controls from day 7 on over the observation
period. To test if the survival potential of A2780 was changed due
to an increased Notch pathway activation, we carried out colony-
forming assays. After 7 days approximately 28712% more
colonies formed from single cells of stably hNotch 1-IC-HA
transfected cells compared to mock transfected controls.
DISCUSSION
In the present study, we have shown differences in the mRNA
and protein expression profile for certain elements of the notch
pathway (receptors, ligands, modulators and downstream signal-
ling factors) between ovarian adenocarcinomas, borderline
tumours and ovarian adenomas: We could show a higher HESl
protein expression in ovarian cancers and borderline tumours in
comparison to adenomas. Transfection experiments with activated
Notch 1 intracellular domain in A2780 ovarian adenocarcinoma
cells indicated a proliferative advantage due to Notch 1 that is
consistent with an impaired contact inhibition at confluence. The
growth advantage of Notch 1-IC transfected A2780 cells in
comparison to empty vector controls was also evident by their
enhanced ability to form colonies from single cells on plastic
surfaces (colony-forming units) (Bashey et al, 1992; Yu et al, 1999).
The magnitude of in vitro growth effects was modest, but similar
to recent observations with c-Myc (Pelengaris et al, 2002), the
contribution to in vivo tumour formation could be significant.
Altered Notch expression has already been observed in cervical
carcinomas (Zagouras et al, 1995), lung cancer (Dang et al, 2003),
pancreatic cancer (Miyamoto et al, 2003), breast cancer (Weijzen
et al, 2002), and endometrium carcinomas (Suzuki et al, 2000). In
early hematopoietic stem cells Notch-signalling stops differentia-
tion and maintains a pool of proliferating pluripotent cells (Milner
and Bigas, 1999; Ohishi et al, 2002; Kunisato et al, 2003). Of
interest, the OSE is closer in its differentiation state to the
pluripotent mesodermal embryonic precursor cells than other
epithelial derivates (Scully, 1995). Although overexpression of
Notch 1 mRNA or protein has not been found in ovarian tumours,
our data point to a possible role of the Notch pathway in ovarian
cancer formation: our transfection experiments indicate, that
activation of the Notch pathway could contribute to the malignant
phenotype by maintaining proliferative activity against growth
control signals and by promoting cell survival. Expression array
data have revealed that at least two members of the Notch-
signalling network may be involved in the ovarian carcinogenesis:
Notch 3 was at least three-fold overexpressed over normal ovarian
surface epithelial cells (Lu et al, 2004) and a similar observation
was reported for Jagged 2 (Euer et al, 2005). These studies did not
identify the same genes as overexpressed in ovarian cancer
although they used similar methods; thus, these finding as well
as our present study should be considered preliminary. How in
detail the Notch pathway exerts its oncogenic function has not
been fully elucidated. A recent study showed that CBF1, the first
major downstream signalling factor of the Notch pathway, when
activated, interacts with the Cyclin Dl promotor, resulting in
increased CD1 activity and Gl/S-phase transition (Ronchini and
Capobianco, 2001). Furthermore Notch-IC activated CBF1 induces
the transcription of NFkB(Oswald et al, 1998).
Besides it has been shown that NFkB controls the expression of
the Notch ligand Jagged 1 in a positive feedback loop (Bash et al,
1999). It is likely, however, that Notch alone is not capable of
transforming cells but requires the functional collaboration of
other oncogenes, namely from the RAS (IRK, MAP kinase, PI3
kinase) (Fitzgerald et al, 2000; Weijzen et al, 2002) and c-Myc
pathways (Rao and Kadesch, 2003). PI3K (Philp et al, 2001) and
c-Myc (Tashiro et al, 1992) overexpression have been reported for
ovarian adenocarcinomas.
Several questions about the function of Notch in ovarian
tumours still remain to be answered. The relevance of other
receptors of the Notch family has not been elucidated yet.
Likewise, it is not known what regulates the degree of Notch
pathway activation in ovarian tumours. The expression pattern of
Notch ligands might play a crucial role though. Interestingly our
preliminary data point to a robust protein expression of Jagged 1
in ovarian tumours. If relevant cell–cell interactions are homo-
typic (between tumour cells themselves) or heterotypic (between
tumour cells and other cells e.g. stroma cells) remains to be
determined.
In summary, the Notch-signalling pathway is operative in
ovarian cancer, and we propose a positive relationship between
Notch pathway activation as indicated by HES1 protein expression
levels and tumour growth in ovarian cancer. This hypothesis will
need to be addressed in further studies. Moreover, elements of the
Notch pathway could be worthwhile targets for future therapies of
ovarian cancer (Jang et al, 2000; Nickoloff et al, 2003) such as
siRNA and gamma-secretase inhibitors (Elbashir et al, 2001;
Kimberly et al, 2003; Micchelli et al, 2003).
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